Dataset Information

MaHPIC Experiment HuB - Metabolomics analysis of human plasma from patients infected with Plasmodium falciparum and P.vivax for discovery of diagnostic markers of malaria

ABSTRACT: MaHPIC Experimental Description:
This study is based on archived plasma from samples collected between 2011 and 2014. Patients in Thailand who were infected with Plasmodium falciparum (30 subjects), P. vivax (30 subjects), co-infected with P. falciparum and P. vivax (22 subjects) were included, alongside two sets of non-malaria cases: non-malarial febrile illnesses (30 subjects) and healthy controls (30 subjects). Malaria subjects were enrolled under ethics research protocol TMEC 11-033, and non-malaria cases were enrolled under TMEC 14-025, both approved by the Ethical Review Committee of the Faculty of Tropical Medicine, Mahidol University, Thailand. All protocols and documentation were reviewed and sample shipments approved by the Emory IRB. Subjects were enrolled at the Ministry of Public Health (MOPH) Malaria Clinics in the Kanchanaburi and Tak provinces clinic between August 2011 and August 2014.

Within the MaHPIC, this project is known as ‘Experiment HuB’. Samples were obtained in collaborations with Jetsumon Prachumsri, Rapathborn Patrapuvich, Viravarn Luvira, Siriwan Rungin, Teerawat Saeseu, and Nattawan Rachaphaew at the Mahidol Vivax Research Unit and the Hospital for Tropical Diseases at Mahidol University. Untargeted metabolomics results were produced by Dean Jones at Emory University. Quantitative Metabolomics using the Biocrates platform results were produced by Dr. Regina Cordy and Manoj Khadka at Emory University. To access other publicly available results from HuB and other MaHPIC Experiments visit http://plasmodb.org/plasmo/mahpic.jsp. This page will be updated as datasets are released to the public.

Complete list of dataset contributors:
The MaHPIC Consortium, Jeremy D. DeBarry, Mary R. Galinski, Dean P. Jones, Manoj Khadka, Jessica C. Kissinger, Shuzhao Li, Viravarn Luvira, Regina Joice Cordy, Esmeralda VS Meyer, Mustafa Nural, Eric A. Ortland, Rapathborn Patrapuvich, Suman B. Pakala, Nattawan Rachaphaew, Teerawat Saeseu, Siriwan Rungin, ViLinh Tran, Jetsumon P. Sattabongkot, Karan Uppal
Please contact the Informatics Core with any questions / concerns / suggestions - mahpic-infocore@uga.edu

Linked Studies: Malaria Host-Pathogen Interaction Center (MaHPIC)

INSTRUMENT(S): Flow Injection Analysis MS - Alternating (FIA-MS (Alternating)), Exactive (Thermo Scientific), Liquid Chromatography MS - Positive (LC-MS (Positive))

SUBMITTER: Jessica Kissinger

PROVIDER: MTBLS664 | MetaboLights | 2018-09-05

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MTBLS664	Other
	FILES	Other
	a_MTBLS664_hub_biocrates_lcms.txt	Txt
	a_MTBLS664_hub_biocrates_neg_fia.txt	Txt
	a_MTBLS664_hub_biocrates_pos_fia.txt	Txt

Items per page:

1 - 5 of 14

Similar Datasets

Project description:MaHPIC Experimental Description: Malaria-naive male rhesus macaques (Macaca mulatta), approximately four years of age, were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. dirus, An. gambiae, and An. stephensi) and then profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, proteomic, and metabolomic measurements. The experiment was designed for 100 days, and pre- and post-100 day periods to prepare subjects and administer curative treatments respectively. The anti-malarial drug artemether was subcuratively administered to all subjects at the initial peak of infection, one out of the five macaques received four additional subcurative treatments for subsequent recrudescence peaks. The experimental infection in one subject was ineffective but the macaque was followed-up for the same period of 100 days. The different clinical phases of the infection were clinically determined for each subject. Blood-stage curative doses of artemether were administered to all subjects at the end of the study. Capillary blood samples were collected daily for the measurement of CBCs, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood and bone marrow samples were collected at seven time points for functional genomic, proteomic, lipidomic, and immunological analyses. Within the MaHPIC, this project is known as ‘Experiment 03’. This dataset was produced by Dr. Regina Cordy and Manoj Khadka at Emory University. To access other publicly available results from 'E03' and other MaHPIC Experiments, including clinical results (specifics on drugs administered, diet, and veterinary interventions), and other omics, visit http://plasmodb.org/plasmo/mahpic.jsp . This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). Complete list of dataset contributors: The MaHPIC Consortium, Jeremy D. DeBarry, Monica Cabrera-Mora, Mary R. Galinski, Manoj Khadka, Jessica C. Kissinger, Regina Joice Cordy, Esmeralda V.S. Meyer, Mustafa Nural, Eric A. Ortland, Rabindra M. Tirouvanziaml Please contact the Informatics Core with any questions / concerns / suggestions - mahpic-infocore@uga.edu Linked Studies: <a href='/metabolights/search?freeTextQuery=MaHPIC' target='_blank'>Malaria Host-Pathogen Interaction Center (MaHPIC)</a>

Project description:The Malaria Host-Pathogen Interaction Center (MaHPIC) is an inter-disciplinary NIH systems biology contract that utilizes multiple omics types (omics, clinical, and mathematical models), to iteratively test and develop hypotheses related to the complex host-parasite dynamics in the course of malaria infections in non-human primates with the goal of better understanding human disease. These data and metadata were produced by MaHPIC in collaborations between Emory University, Georgia Institute of Technology, and The University of Georgia as part of the MaHPIC contract (NIAID Contract: # HHSN272201200031C). Curation and maintenance of these data and metadata are the responsibility of the MaHPIC. Mary Galinski mgalins@emory.edu (MaHPIC Program Director), Jessica Kissinger jkissinger@uga.edu (MaHPIC Co-Program Director), Esmeralda Meyer evargas@emory.edu - MaHPIC Project Manager The experimental design of this pyrimethamine administration experiment with Macaca mulatta was approved by the Emory University Institutional Animal Care and Use Committee (IACUC) and is as follows. Five naive males (RCs13, RWr13, RUn13, RZe13 and RTi13) approximately 2 years of age were injected intravenously with a preparation of Anopheles dirus salivary gland material and then profiled for clinical and omic measurements over the course of a 100-day experiment. Samples were generated and analyzed as part of a multi-omic approach to understanding the effects that the anti-malarial drug pyrimethamine has on immune physiology in rhesus macaques (M. mulatta). There was no infection with Plasmodium parasites during this study. Whole blood and bone marrow RNA-Seq and plasma have been obtained for seven time-points before, during and after three rounds of drug administration. Samples are from either whole blood or bone marrow specimen types. 5 individuals were sampled for each specimen type, 7 times each over the 100 day experiment. 5 individuals * 2 specimen types * 7 time points = 70 samples. Biological samples (Whole Blood or Bone Marrow) were collected at 7 time points during the 100 days. These correspond to: Time Point 1 = Day 0 (Baseline Sampling Point) Time Point 2 = Day 21 Time Point 3 = Day 27 Time Point 4 = Day 52 Time Point 5 = Day 59 Time Point 6 = Day 90 Time Point 7 = Day 98 Pyrimethamine was administered on Days 21, 52, 53, 54, 90, 91, and 92.

Project description:Telemetry devices (DSI, model L11) with blood pressure sensors and electrocardiogram (ECG) leads were surgically implanted in two malaria-naive male rhesus macaques (Macaca mulatta), approximately three years of age. After a resting period of two weeks, physiological data that include activity, temperature, ECG, and blood pressure were continuously collected. Two weeks after activation of the telemetry implant, the macaques were inoculated intravenously with cryopreserved P. knowlesi Malayan strain salivary gland sporozoites, obtained from Anopheles dirus infected with parasites from the Pk1A+ clone. The P. knowlesi sporozoites were produced, isolated and cryopreserved at the Centers for Disease Control and Prevention. After inoculation, the macaques were profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, proteomic, metabolomic, telemetric and histopathological measurements. The experiment was designed for pathology studies, with terminal necropsies on days 11 (RKy15) or 19 (Red16). The anti-malarial drug artemether was subcuratively administered selectively to one subject (REd16) during the primary parasitemia to suppress clinical complications. Capillary blood samples were collected daily for the measurement of complete blood counts, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood and bone marrow samples were collected at five timepoints for functional genomic, proteomic, lipidomic, and immunological analyses. Physiological data were continuously captured via telemetry. Within the MaHPIC, this project is known as 'Experiment 30'. This dataset was produced by Dr. Regina Cordy and Manoj Khadka at Emory University. To access other publicly available results from 'E30' and other MaHPIC Experiments, including clinical results (specifics on drugs administered, diet, and veterinary interventions), and other omics, visit <a href='http://plasmodb.org/plasmo/mahpic.jsp' target='_blank'>http://plasmodb.org/plasmo/mahpic.jsp</a>. This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC) and the MRMC Office of Research Protection Animal Care and Use Review Office (ACURO). Linked Studies: <a href='/metabolights/search?freeTextQuery=MaHPIC' target='_blank'>Malaria Host-Pathogen Interaction Center (MaHPIC)</a>

Project description:Project Description: The Malaria Host-Pathogen Interaction Center (MaHPIC) is a transdisciplinary malaria systems biology research program initially supported by an NIH/NIAID contract (HHSN272201200031C, 2012-2017; see <a href='http://www.systemsbiology.emory.edu' target='_blank'>http://www.systemsbiology.emory.edu</a>). The MaHPIC continues with ongoing support from the Defense Advanced Research Project Agency (DARPA) and others. The MaHPIC generates many data types (e.g., clinical, hematological, parasitological, metabolomics, functional genomics, lipidomics, proteomics, immune response, telemetry) and mathematical models, to iteratively test and develop hypotheses related to the complex host-parasite dynamics in the course of malaria in non-human primates (NHPs), and metabolomics data via collaborations with investigators conducting clinical studies in malaria endemic countries, with the overarching goal of better understanding human disease, pathogenesis, and immunity. Curation and maintenance of all data and metadata are the responsibility of the MaHPIC. MaHPIC Experiment Description: Sixteen healthy volunteers, 7 malaria naïve and 9 semi-immune, aged 18-45 years, were enrolled in this study during October 2012 to November 2013. Malaria-naive volunteers were recruited in Cali, Colombia, a non-endemic city; those with previous malaria experience were recruited in Buenaventura, a malaria-endemic area on the Colombian Pacific Coast. The study was approved by Institutional Review Boards (IRB) of the Malaria Vaccine and Drug Development Center–MVDC (CECIV, Cali) and Centro Médico Imbanaco (Cali). All protocols and documentation were reviewed and samples shipments approved by the Emory IRB. Male and female patients were eligible for inclusion, which included two steps: 1) age between 15-60 years, hemoglobin levels > 9g/dL, presence of current Plasmodium vivax infection, absence of other Plasmodium species determined by thick blood smear and PCR, blood parasite count of 0.1% or more, absence of other acute or chronic diseases, being able to sign an informed consent form; 2) healthy 18 to 45 years old man or non-pregnant women, capacity to sign an informed consent in a free and voluntary way, acceptable understanding of the clinical trial through the approval of a questionnaire regarding the information given in the consent process, obligatory use of adequate contraceptive method from beginning of recruitment and screening time up to three months after last immunization, do not have chronic or acute diseases, accept not traveling to malaria endemic areas during the clinical trial, have telephone at home or mobile phone that permit permanent contact for follow up, being willing to participated during both steps of the clinical trial. Exclusion criteria included pregnancy, abnormal laboratory test values, hemoglobin pathology, glucose-6-phosphate dehydrogenase (G6PDH) deficiency, positive for blood bank infectious diseases (syphilis, HIV, Chagas disease, HTLV 1–2, and hepatitis B and hepatitis C), or have any condition that would increase the risk of an adverse outcome. Volunteers were infected with P. vivax via sporozoite challenge by exposing volunteers to bites of 2–4 mosquitoes (Anopheles albimanus) of the same infected batch. Plasma samples were collected at 4 time points: Baseline, 1 month pre-inoculation; Diagnosis; 3 weeks post-treatment; 4 months post-treatment. As soon as parasites were detected by thick blood smears, participants were treated orally with curative doses of chloroquine (1500 mg chloroquine provided in three doses: 600 mg initially then 450 mg doses at 24 and 48 hours) and primaquine (30 mg dose given once per day for 14 days). Clinical trial registration: NCT01585077. Samples were analyzed with liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS), evaluated in a time course and between naïve and semi-immune volunteers. Within the MaHPIC, this project is known as ‘Experiment HuC’. Samples were obtained in collaboration with Socrates Herrera from the Malaria Vaccine and Drug Development Center, Colombia. Metabolomics results were produced by Dean Jones at Emory University. To access other publicly available results from HuC and other MaHPIC Experiments visit <a href='http://plasmodb.org/plasmo/mahpic.jsp' target='_blank'>http://plasmodb.org/plasmo/mahpic.jsp</a> . This page will be updated as datasets are released to the public. The following contributed to the creation of this dataset: The MaHPIC Consortium, Jeremy D. DeBarry, Mary R. Galinski, Luiz G. Gardinassi, Socrates Herrera, Myriam Arévalo-Herrera, Dean P. Jones, Jessica C. Kissinger, Shuzhao Li, Regina Joice Cordy, Esmeralda VS Meyer, Mustafa V. Nural, Suman B. Pakala, ViLinh Tran, Karan Uppal Linked Studies: <a href='/metabolights/search?freeTextQuery=MaHPIC' target='_blank'>Malaria Host-Pathogen Interaction Center (MaHPIC)</a>

Project description:Malaria-naive male rhesus macaques (Macaca mulatta), approximately four years of age, were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. dirus, An. gambiae, and An. stephensi) and then profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, proteomic, and metabolomic measurements. The experiment was designed for 100 days, and pre- and post-100 day periods to prepare subjects and administer curative treatments respectively. The anti-malarial drug artemether was subcuratively administered to all subjects at the initial peak of infection, one out of the five macaques received four additional subcurative treatments for subsequent recrudescence peaks. The experimental infection in one subject was ineffective but the macaque was followed-up for the same period of 100 days. The different clinical phases of the infection were clinically determined for each subject. Blood-stage curative doses of artemether were administered to all subjects at the end of the study. Capillary blood samples were collected daily for the measurement of CBCs, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood and bone marrow samples were collected at seven time points for functional genomic, proteomic, lipidomic, and immunological analyses. Within the MaHPIC, this project is known as 'Experiment 03'. This dataset was produced by Dean Jones at Emory University. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). To access other publicly available results from E03 and other MaHPIC Experiments, including clinical results (specifics on drugs administered, diet, and veterinary interventions), and other omics, visit <a href=http://plasmodb.org/plasmo/mahpic.jsp>http://plasmodb.org/plasmo/mahpic.jsp</a> This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). Linked Studies: <a href='/metabolights/search?freeTextQuery=MaHPIC' target='_blank'>Malaria Host-Pathogen Interaction Center (MaHPIC)</a>

Project description:Malaria-naive male rhesus macaques (Macaca mulatta), approximately three years of age, were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. dirus, An. gambiae, and An. stephensi) and then profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, proteomic, and metabolomic measurements. The experiment was designed for 100 days, and pre- and post-100 day periods to prepare subjects and administer curative treatments respectively. The anti-malarial drug artemether was subcuratively administered selectively to several subjects during the primary parasitemia to suppress clinical complications and to all animals for curative treatment of blood-stage infections to allow detection of relapses. One subject was euthanized during the 100-day experimental period due to clinical complications. The anti-malarial drugs primaquine and chloroquine were administered to all remaining subjects at the end of the study for curative treatment of the liver and blood-stage infections, respectively. Capillary blood samples were collected daily for the measurement of CBCs, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood and bone marrow samples were collected at seven time points for functional genomic, proteomic, lipidomic, and immunological analyses. Within the MaHPIC, this project is known as Experiment 04. This dataset was produced by Dean Jones at Emory University.To access other publicly available results from E04 and other MaHPIC Experiments, including clinical results (specifics on drugs administered, diet, and veterinary interventions), and other omics, visit <a href=http://plasmodb.org/plasmo/mahpic.jsp>http://plasmodb.org/plasmo/mahpic.jsp</a> This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). Linked Studies: <a href='/metabolights/search?freeTextQuery=MaHPIC' target='_blank'>Malaria Host-Pathogen Interaction Center (MaHPIC)</a>

Project description:Telemetry devices (DSI, model L11) with blood pressure sensors and electrocardiogram (ECG) leads were surgically implanted in four malaria-naive male rhesus macaques (Macaca mulatta), approximately five years of age. After a resting period of two weeks, physiological data that include activity, temperature, ECG, and blood pressure were continuously collected. Two weeks after activation of the telemetry implant, the macaques were inoculated intravenously with cryopreserved P. knowlesi Malayan strain salivary gland sporozoites, obtained from Anopheles dirus infected with parasites from the Pk1A+ clone and previously tested in E30 for their infectivity of macaques. The sporozoite stocks used were produced, isolated and cryopreserved at the Centers for Disease Control and Prevention, and then stored at Yerkes. After inoculation, the macaques were profiled longitudinally for clinical, hematological, parasitological, immunological, functional genomic, proteomic, and metabolomic measurements. The experiment was designed with pathology studies and thus terminal necropsies, which were scheduled at the log phase of the infections or at the peak of parasitemias. Capillary blood samples were collected daily for the measurement of complete blood counts, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomics analyses. Venous blood and bone marrow samples were collected at five timepoints for functional genomic, targeted proteomic, targeted metabolomics, and immunological analyses. Physiological data noted above were continuously captured via the implanted telemetry devices. Within the MaHPIC, this project is known as 'Experiment 06'. This dataset was produced by Dr. Regina Cordy and Manoj Khadka at Emory University. To access other publicly available results from E06 and other MaHPIC Experiments, including clinical results (specifics on drugs administered, diet, and veterinary interventions), and other omics, visit <a href='http://plasmodb.org/plasmo/mahpic.jsp'>plasmodb.org/plasmo/mahpic.jsp</a>. This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC) and the MRMC Office of Research Protection Animal Care and Use Review Office (ACURO). Linked Studies: <a href='/metabolights/search?freeTextQuery=MaHPIC' target='_blank'>Malaria Host-Pathogen Interaction Center (MaHPIC)</a>

Dataset Information

MaHPIC Experiment HuB - Metabolomics analysis of human plasma from patients infected with Plasmodium falciparum and P.vivax for discovery of diagnostic markers of malaria

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets